Literature DB >> 32484628

Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes.

Andrew Blauvelt, Jashin J Wu, April Armstrong, Alan Menter, Clive Liu, Abby Jacobson.   

Abstract

Psoriasis is associated with physical, psychological, social, and economic burdens that lead to substantial impairment over a patient’s lifetime. It is important to understand how different skin clearance levels may relate to patient perceptions of psoriasis symptoms and health-related quality of life. Here, we highlight notable advantages to complete skin clearance relative to high levels of efficacy without complete skin clearance, including meaningful improvements in patient-reported signs and symptoms of psoriasis, a higher mean proportion of symptom-free days, and significant improvements in quality of life. We also review biologic therapies associated with high percentages of complete skin clearance and significant improvements in signs and symptoms of psoriasis, notably brodalumab. These therapies are likely to play important roles in the future treatment of moderate-to-severe psoriasis, given that improvement in quality of life is of significant value relative to biologics or other systemic therapies associated with lower rates of complete skin clearance. J Drugs Dermatol. 2020;19(5): doi:10.36849/JDD.2020.4957.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32484628

Source DB:  PubMed          Journal:  J Drugs Dermatol        ISSN: 1545-9616            Impact factor:   2.114


  2 in total

1.  Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare.

Authors:  Rosa Romero-Jimenez; Vicente Escudero-Vilaplana; Esther Chamorro-de-Vega; Arantza Ais-Larisgoitia; Elena Lobato-Matilla; Beatriz Somoza-Fernández; Paula Ruiz-Briones; Carlos González; Ofelia Baniandrés; Luis Menchén; Carmen Lobo-Rodríguez; Ana Herranz; María Sanjurjo
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

2.  Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.

Authors:  Boni E Elewski; Andrew Blauvelt; Gaia Gallo; Eric Wolf; Missy McKean-Matthews; Russel Burge; Joseph F Merola; Alice B Gottlieb; Lyn C Guenther
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.